Skip to main content

Menu

BNF January 2022 Update

This update contains 9 significant changes, 2 dose changes, 5 new monographs and 1 deleted preparation.

Significant Changes:

  • Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use [MHRA/CHM advice].
  • Arrhythmias: updated guidance for the management of atrial fibrillation.
  • COVID-19: updated guidance.
  • COVID-19 vaccines: updated guidance in-line with Public Health England/UK Health Security Agency recommendations.
  • Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus [MHRA/CHM advice].
  • Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
  • Mexiletine: update to include new indication for life-threatening ventricular arrhythmias.
  • Phenobarbital: oral doses for children have been removed from the BNF; these can still be accessed in BNF for Children, where additional information on the available oral solutions and advice from the RCPCH/NPPG can be found in the prescribing and dispensing section of the Phenobarbital monograph.
  • Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist [MHRA/CHM advice].

Dose Changes:

  • Adrenaline/epinephrine [update to dosing for acute anaphylaxis].
  • Calcium gluconate [update to dosing for acute severe hyperkalaemia].

New Monographs:

  • Lagevrio® [molnupiravir].
  • Lumykras® [sotorasib].
  • Ponvory® [ponesimod].
  • Tepmetko® [tepotinib].
  • Tukysa® [tucatinib].

Deleted Preparations: Tacni® [tacrolimus].

For further details on changes in the BNF click on  https://www.medicinescomplete.com/#/content/bnf/PHP107699